Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* • HCV infection~  * Adult patients, 18years and older.~Exclusion Criteria:~* • Child score \> 12~  * Severe Renal impairment~ * Pregnant and lactating women~ * HCC or other malignant neoplasms~ * Co-infection with human immunodeficiency virus (HIV)~ * Co-infection with hepatitis B virus (HBV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sof-Riba (Type: ACTIVE_COMPARATOR): Sofosbuvir ribavirin 6 months.
- Sof- Riba- Pegylated interferon (Type: ACTIVE_COMPARATOR): Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
- Sof- Olysio (Type: ACTIVE_COMPARATOR): Sofosbuvir and simeprevir for 3 months.
- Sof- Dacla (Type: ACTIVE_COMPARATOR): Sofosbuvir and Daclatasvir for 3 months.
- Harvony (Type: ACTIVE_COMPARATOR): Sofosbuvir and ledipasvir for 3 months
- Ritaprevir, paritaprevir, ombetasvir (Type: ACTIVE_COMPARATOR): Querevo for 3 months
- Salvage therapy (Type: ACTIVE_COMPARATOR): sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo

Based on this trial design, predict the completion outcome and termination type (if applicable).